Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 82Neoplasms 47Carcinoma, Non-Small-Cell Lung 28Colorectal Neoplasms 20Neoplasm Metastasis 15Multiple Myeloma 14Thyroid Neoplasms 13Glioma 12Pancreatic Neoplasms 11Hematologic Neoplasms 10Thyroid Carcinoma, Anaplastic 9Brain Neoplasms 8Lung Neoplasms 7Triple Negative Breast Neoplasms 5Skin Neoplasms 5Rectal Neoplasms 5Neurofibromatosis 1 5Lymphoma 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Breast Neoplasms 5Astrocytoma 5Thyroid Cancer, Papillary 4Recurrence 4Prostatic Neoplasms 4Neurofibroma, Plexiform 4Glioblastoma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uveal Melanoma 3

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Taxes 17Specimen Handling 17Docetaxel 17Nivolumab 16Magnetic Resonance Spectroscopy 16dostarlimab 15Metformin 15Blood Specimen Collection 14Observation 13Gemcitabine 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × trametinib × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

GlaxoSmithKline

Phase 1 Completed
240 enrolled
BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡